Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Badros, Ashraf ^{[2
]}

Popat, Rakesh ^{[3
]}

Rodriguez-Otero, Paula ^{[4
]}

Farooq, Asim ^{[5
]}

Jeng, Bennie ^{[2
]}

Degli Esposti, Simona ^{[6
,7
]}

Lewis, Eric

Gupta, Ira ^{[8
,9
]}

Opalinska, Joanna ^{[9
]}

Palumbo, Antonio ^{[10
]}

Trudel, Suzanne ^{[11
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[3] Univ Coll London Hosp NHS Fdn Trust, London, England

[4] Univ Navarra Clin, Inst Invest Sanitaria Navarra, Navarra, Spain

[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England

[7] UCL Inst Ophthalmol, London, England

[8] GlaxoSmithKline, Res Triangle Pk, NC USA

[9] GlaxoSmithKline, Upper Providence, PA USA

[10] GlaxoSmithKline, Zug, Switzerland

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

关键词：

belantamab mafodotin; B-cell maturation antigen; BCMA; multiple myeloma; ocular;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-103

引用

页码：S421 / S421

页数：1